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Abstract 
Background: Infectious complications in febrile neutropenic patients are still major causes of morbidity and mortality despite significant 
advances in diagnostic techniques and antimicrobial therapy. In this study, we describe the characteristics of patients with hematological 
malignancies who were evaluated for suspected infection. This study was also conducted to assess the isolation rate of bacterial and fungal 
causative agents in febrile neutropenic attacks. 
Method: The study was conducted at Pamukkale University Hospital, Turkey. In order to identify the characteristics of patients with 
hematological malignancies in the presence/suspicion of any accompanying infectious disease, patients’ charts with hematological 
malignancies were reviewed for signs/symptoms of any infection between October 1, 2001, and May 31, 2005, retrospectively. 
Results: Overall, 90 infectious episodes occurred in 59 patients. The most common underlying diseases were acute myelogenous leukemia 
(61.0%) and acute lymphocytic leukemia (15.3%). The absolute neutrophil count was lower than 100/mm³ in 33 (36.7%) episodes. 
Microbiologically and clinically documented infections and fever of unknown origin were observed in 35.6%, 28.9%, and 35.6% of the 
participants, respectively. Bloodstream infections and pneumonia were detected in 21.1% and 18.9% of episodes, respectively. Gram 
negative organisms were most common (58.4%), followed by gram positive cocci. A combination of third generation cephalosporin and an 
aminoglycoside were used in 44.4% of episodes initially. Fever resolved in 24.4% of episodes using the initial therapy. The mortality rate 
was 15.6%. 
Conclusion: These results showed that infections with gram-negative bacteria continue to predominate in febrile neutopenic episodes in our 
center. 
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Introduction 
Infectious complications in febrile neutropenic 
patients are still major causes of morbidity and 
mortality despite significant advances in diagnostic 
techniques and antimicrobial therapy. Frequently, the 
bacterial aetiology is unknown at the onset of infection 
[1,2]. There were major changes in the type and range 
of pathogens causing infection in neutropenic patients 
during the last decades. Gram-negative bacteria were 
more prevalent before the mid-1980s. However, Gram-
positive cocci, generally considered to be less virulent, 
especially coagulase negative staphylococci, have 
become increasingly common since the mid 1980s. But 
since the begginning of the new century, Gram-negative 
bacilli have re-emerged [3,4]. 
The clinician must have knowledge of the 
prevalence of causative bacteria in neutropenic patients 
with fever and their antibiotic susceptibilities in the 
local area in order to choose the proper antibiotic. In 
this study, we describe the characteristics of 
neutropenic patients with hematological malignancies 
who were evaluated for suspected infection. The study 
was also conducted to assess the isolation rate of 
bacterial and fungal causative agents in febrile 
neutropenic attacks. 
 
Materials and Methods 
The study was conducted at Pamukkale University 
Hospital, Denizli, Turkey. In order to identify the 
characteristics of patients with hematological 
malignancies in the presence/suspicion of any 
accompanying infectious disease, patients with 
hematological malignancies evaluated for 
signs/symptoms of any infection between October 1, 
2001, and May 31, 2005, were retrospectively reviewed. 
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Patients were eligible if they had a single 
measurement of oral temperature 38.5° or 38.0°C on 
two or more occasions within 12 hours, and the fever 
was not related to the administration of blood products 
or known pyrogenic substances [5]. All patients were 
evaluated by thorough physical examination. Blood 
cultures were taken from a central or a peripheral vein 
before antibiotic initiation and every 24 hours thereafter 
during persistent fever until culture results became 
negative. Bacterial blood-stream infection was defined 
as the presence of clinical symptoms in association with 
one, of a set of two, positive cultures when the isolated 
pathogen was a gram-negative agent or associated with 
two or more positive blood cultures when the pathogen 
isolated was a gram-positive agent. When fungal 
species were isolated from one or more blood cultures, 
it was accepted as fungal blood-stream infection [6]. 
Additionally, cultures from urine samples and, if 
appropriate, from other suspected body sites were 
obtained. All patients were evaluated by a complete 
blood count and urine analysis, and standard blood 
chemistry.  
A febrile episode was determined as a 
microbiologically documented infection when 
bloodstream infection was verified or cultures showed 
growth from a site of infection; a clinically documented 
infection when a suspected site of infection was 
identified without microbiological confirmation; and a 
fever of unknown origin when no site was identified 
and no microbiological evidence of infection was 
found. All organisms isolated from clinical specimens 
were identified by standard criteria in our clinical 
microbiology laboratory [7]. 
Patients were given empirical antibiotic therapy 
when a febrile neutropenic episode was defined while 
awaiting the culture results. In patients with 
microbiologically documented infection, treatment was 
modified according to the isolated pathogen and its 
susceptibility. A treatment modification was not done 
before 72 hours unless a resistant microorganism was 
cultured during that period or the patient’s condition 
notably deteriorated. 
 
Statistical analysis 
All data are described as mean ± SD. Continuous 
variables were compared using the independent-samples 
t test and categorical variables were compared using the 
chi-square test or Fisher’s exact test for association. 
Differences were considered statistically significant 
when P < 0.05. Data were analyzed by statistical 
software (SPSS for Windows 11.0; SPSS, Chicago, 
Illinois). 
 
Results 
Overall, 90 infectious episodes occurred in 59 
patients. Table 1 summarises the demographic data for 
the patients with febrile neutropenic attacks included in 
the study. The absolute neutrophil count (ANC) was 
between 500 and 1000/mm
3
 in 27 (30%) episodes, 
between 100 and 500/mm
3
 in 30 (33.3%) episodes and 
lower than 100/mm³ in 33 (36.7%) episodes. In the 
patients with bloodstream infection, the ratio of ANC 
below 100/mm
3
 and between 100 and 500/mm3 was 
52.6% (10) and 47.4% (9), respectively. The mean 
count of cultures was 9.2±6.8 (3-29).  
 
Table 1. Demographic data for 59 patients with febrile 
neutropenic attacks. 
Variable 
Febrile neutropenic 
patients 
Age (yr; mean+SD; range) 48.3+18.9 (18-80) 
Gender (Male) N (%) 76.3% 
Underlying disease; n (%) 
   Acute myelogenous leukemia 
   Acute lymphocytic leukemia 
   Non-Hodgkin’s lymphoma 
   Idiopatic neutropenia 
  Others (aplastic anemia, chronic granulocytic 
leukomia, and hairy-cell leukemia, etc) 
 
61.0% 
15.3% 
5.1% 
5.1% 
13.5% 
 
 
Mean duration of fever (day; mean+SD; range) 11±7.3 (2-42) 
Mean duration of antibiotic treatment (day; mean 
+ SD; range) 
15.6±7.6 (5-46) 
Death 14 (15.6%) 
 
Microbiologically and clinically documented 
infections and fever of unknown origin were observed 
in 35.6%, 28.9%, and 35.5% of the participants, 
respectively. Blood-stream infections and pneumonia 
were detected in 19 episodes (21.1%) and 17 episodes 
(18.9%), respectively. In 56.3% of culture-proven 
episodes (18 cases), blood-stream infection was 
considered the cause of fever, followed by pneumonia 
in 15.6% (five cases), and by urinary tract infections in 
12.5% (4 events) (Table 2). A single pathogen was 
isolated in 28 of the culture positive episodes and two 
patogens in four. Microbiologically, gram negative 
organisms (58.4%) (Escherichia coli, Pseudomonas 
aeruginosa, Klebsiella pneumonia) were most common, 
followed by gram positive (Staphylococcus epidermidis, 
S. aureus) (Table 3). There were three ESBL producing 
gram-negative bacilli (two E. coli and one K. 
pneumoniae). Susceptibility patterns in gram-negative 
isolates are given in Table 4. Resistance to oxacillin 
was detected in three (75%) of S. aureus and two 
(28.6%) of S. epidermidis. No glycopeptide-resistant 
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gram-positive isolates were isolated. None of the 
streptococcal isolates was penicillin resistant. The ratio 
of gram-positive and gram-negative microorganisms 
causing blood-stream infections was equal (50%). E. 
coli (five isolates; 27.8%) was the predominant 
microorganism isolated from bloodstream infections, 
followed by methicillin-sensitive S. epidermidis (four 
isolates; 22.2%) and methicilline resistant S. aureus 
(three isolates; 16.7%) (Table 5). One of the E. coli 
strains isolated from the subsequent episodes was 
ESBL, while no ESBL strain was isolated from the 
initial episodes. Similarly, resistance to oxacillin among 
the isolated staphylococci from blood was determined 
to be higher in the subsequent episodes in comparison 
with the initial ones. During the study there was neither 
an outbreak nor a cluster of cases due to a specific 
microorganism. 
 
Table 2. Infectious complications identified during the study 
period. 
Type of infection Number % 
Microbiologically documented infections 
Blood stream infections 
Pneumonia 
Urinary tract infections 
Gastrointestinal tract infections 
Skin, soft tissue infections 
Central nervous system infections 
32 
18 
5 
4 
3 
1 
1 
35.6 
56.3 
15.6 
12.5 
9.4 
3.1 
3.1 
Fever of unknown origin 32 35.5 
Clinically documented infections 
Pneumonia 
Skin, soft tissue infections 
Urinary tract infections 
Gastrointestinal tract infections 
Perianal infections 
Blood stream infections 
26 
12 
4 
4 
3 
2 
1 
28.9 
46.2 
15.4 
15.4 
11.5 
7.7 
3.8 
Total 90 100 
 
Table 3. Pathogens isolated in febrile neutropenic attacks. 
Microorganism Number % 
Gram-negative bacilli 
Escherichia coli 
Klebsiella pneumonia 
Pseudomonas aeruginosa 
Enterobacter spp. 
Acinetobacter spp. 
21 
9 
4 
4 
2 
2 
58.4 
25 
11.1 
11.1 
5.6 
5.6 
Gram-positive bacteria 
MSSE 
MRSA  
MRSE 
Streptococcus viridans  
MSSA 
13 
5 
3 
2 
2 
1 
36.1 
13.9 
8.3 
5.6 
5.6 
2.8 
Fungi 
Candida albicans  
Non-albicans candida 
2 
1 
1 
5.6 
2.8 
2.8 
Total 36 100 
MSSE=Methicilline sensitive S. epidermidis, MRSA: Methicillin resistant S. aureus, 
MRSE=Methicillin resistant S. epidermidis, MSSA= Methicillin sensitive S. aureus. 
 
The most commonly used initial therapies were a 
combination of third generation cephalosporin and an 
aminoglycoside (44.4%), antipseudomonal betalactam-
betalactamase inhibitors (12.2%) and carbapenems 
(11.1%). Fever resolved in 24.4% of episodes using the 
initial therapy; in the remainder, second-line antibiotics 
(mainly glycopeptyde) and antifungals (amphotericin-
B) were added empirically or depending on culture and 
sensitivity. Antibiotics were discontinued when initial 
blood cultures had no growth after at least 48 hours and 
no source of infection was found, the blood count was 
improving, and if the patient became afebrile and 
clinically well. A total of 14 patients (15.6%) died 
during the infectious episode. Gram-positive 
microorganisms were found in five patients (35.7%), 
while gram-negative microorrgansims were isolated 
from four patients (28.6%). 
 
Table 4. Susceptibility patterns in Gram-negative bacilli 
(percentage of resistance to tested antibiotics). 
Bacteria AK AMP CTX CEFT CRP IMP TMP 
Escherichia coli 11 100 22 22 33 0 89 
Klebsiella pneumonia 0 50 25 25 0 0 100 
Pseudomonas aeruginosa 25 100 100 50 50 0 100 
Enterobacter spp. 50 100 50 50 0 0 100 
Acinetobacter spp. 50 100 100 100 0 0 100 
AK = amikacin; AMP = ampicillin; CTX = cefotaxime; CEFT = ceftazidime; CRP = 
ciprofloxacin; IMP = imipenem; TMP = trimethoprim-sulfamethoxasole. 
 
Table 5. Microorganisms isolated from the patients with 
blood stream infection. 
Microorganism Initial 
episode 
(n) 
Subsequent 
episodes 
(n) 
Total 
N % 
Gram-negative bacilli 
Esherichia coli 
Acinetobacter spp. 
Klebsiella pneumonia 
Pseudomonas aeruginosa 
4 
2 
1 
1 
0 
5 
3 
1 
0 
1 
9 
5 
2 
1 
1 
50 
27.7 
11.1 
5.6 
5.6 
Gram-positive bacteria 
Methicilline sensitive S. epidermidis 
Methicillin resistant S. aureus 
Methicillin resistant S. epidermidis 
Streptococcus viridans  
3 
2 
1 
0 
0 
6 
2 
2 
1 
1 
9 
4 
3 
1 
1 
50 
22.2 
16.6 
5.6 
5.6 
Total 7 11 18 100 
 
There was no statistically important difference 
between the deaths due to gram-positive and negative 
microorganisms (P>0.05). The death ratio in the patient 
group with blood-stream infection was 26.3%, whereas 
in the group without blood-stream infection the death 
ratio was 12.7%. There was no statistically important 
difference between the groups in accordance to death 
ratio (P>0.05).  
 
Discussion 
Febrile neutropenia is a potentially life-threatening 
situation, as severe infections are common, requiring 
prompt medical intervention [8-10]. Identification of the 
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causative microorganisms of infection is possible in 
only 22% to 39% of cases [2,9]. 
According to the recent reports, gram-negative 
bacilli have re-emerged as the dominant pathogens in 
febrile neutropenic patients in some European centres. 
On the other hand, data from the Surveillance and 
Control of Pathogens of Epidemiologic Importance 
(SCOPE) Project reports that gram-positive cocci still 
predominate in the USA [11-13]. 
Gram negative bacilli were the most commonly 
isolated microorganisms in our study, followed by gram 
positive cocci. Although the ratio of causative gram-
positive and gram-negative agents of blood-stream 
infection was equal, E. coli was the predominant one 
(27.8%). The possible reason that gram-negative baciili 
are predominant in our neutropenic patients is that we 
do not use flouroquinolones and cotrimoxasole as 
prophilactic agents and catheters are used only as  
required. 
Analysis of data from Turkey over an 18-year 
period showed that the Gram-negative bacilli were the 
dominant isolates with a ratio of 52% (243/468), but 
they accounted for only 41.5% of bloodstream 
infections [14]. On the other hand, a multicenter study 
from our country reported that 79% of all bacteraemic 
episodes (11 of 14) were caused by Gram-positive 
bacteria [15]. As it is obviously seen, there are 
significant differences in the epidemilogical profiles 
among the areas in our country. Recent studies from 
other developing countries also report different results 
[16,17]. 
Additionally, an increasing frequency of infections 
caused by fungi and an increased mortality due to them 
has been reported [18]. However, only two fungal 
infections were detected in our study. The incidance of 
streptococcal infections in cancer patients has also been 
rising for the past years and the viridans streptococci 
have now become one of the frequently organisms from 
blood-stream infection in neutropenic patients [19]. 
Streptococcus viridans accounted for 5.6% of isolated 
microorganisms from all patients in our study. The ratio 
of this pathogen was the same for the blood-stream 
infection. 
In the present study, blood-stream infection was 
found to be the most common infection in our febrile 
neutropenic patients. Sigurdardottir et al. found that the 
ratio of gram-negative and gram-positive bacteria 
among the isolated pathogens from the patients with 
blood-stream infections was 49.2% and 45.9%, 
respectively [20]. As in our study, the most frequent 
isolated bacteri was E. coli (%25.4). On the other hand, 
Gaytan-Martinez et al. also found blood-stream 
infection to be the predominant infection in their febrile 
neutropenic patients, but it was due mainly to gram-
positive cocci [6]. 
In the present study, infection was 
microbiologically or clinically documented in 58 
episodes (64.5%). In a multicenter study reported from 
our country, that ratio was 69% [15]. Dikici et al. 21 
were more successful in the isolation of 
microorganisims with a ratio of 42.7%. The ratio of 
fever of unknown origin (36.6%) was similar to ours. 
The incidence of infection is demonstrated to be 
correlated with a granulocyte count of 27 and 
bacteremia usually develops when neutrophils fall to 
<100/mm
3 
[10,12]. Dikici et al. [21] reported that ANC 
was below 100/mm
3
 in 32.9% of the episodes, which is 
slightly lower than our result. The ratio of ANC below 
100/mm3 in the patients with bloodstream infection was 
37%, while in our study it was 52.6%. The mean 
antibiotic usage duration was shorter approximately by 
five days than the duration found in our study (10.8 ± 
5.1 days). A study from our country reported that fever 
persisted for 1 to 30 days in their neutropenic patients, 
while this duration in our study was 2 to 42 days [22]. 
Continious surveillance in local hospitals is also 
important for the monitoring of rates of resistant 
organisms. A study of the incidence of ESBL-producing 
K. pneumoniae among febrile neutropenic paediatric 
patients found that 51.6% of isolates were ESBL 
producers [23]. The fact that ESBL-producing E. coli 
and K. pneumonia were also found in our study should 
be kept in mind when a patient with persistent fever in 
our center does not respond to the given therapy. 
Our preferred regimen in the initial therapy was the 
combination of third-generation cephalosporin and an 
aminoglycoside. The combination of an anti-
pseudomonal beta-lactam and an aminoglycoside has 
been the treatment most frequently used as the initial 
empirical therapy of suspected infections in febrile 
neutropenic patients, especially in those with high risk 
factors for infection [5]. We used this regimen in 12.2% 
of the patients. Recent studies demonstrated that 
monotherapy can successfully replace combination 
therapy in febrile neutropenic patients [25]. 
Imipenem was observed to be the most efficient 
antibiotic to gram-negative microorganisms. Similarly, 
Sigurdardottir et al. found that the most efficient 
antibiotics against the isolated gram negative 
microorganisms were imipenem and ciprofloxacin [20]. 
Fever resolved only in 24.4% of episodes using the 
initial therapy; in the remainder, second-line 
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antimicrobials had to be added empirically or depending 
on culture and sensitivity. As is described in the 
guidelines, glycopeptydes and/or antifungals were 
added when there was no response to the previous 
therapy [5,12,24]. A study from our country reported 
that an antibiotic therapy was modified in more than 
half of the episodes [26]. 
The overall mortality rate among our febrile 
neutropenic patients was 15.6%, while it was as high as 
26.3% in the patients with blood-stream infection. 
Recent studies from our country reported that the 
mortality rate among febrile neutropenic patients was 
11.6% [16,21].  
 
Conclusion 
The shift toward gram-positive organisms and the 
continuing need to provide gram-negative coverage 
demands the use of an agent or agents that provide 
coverage for the spectrum of potential infecting 
organisms. Studies reporting local microbiological 
findings are necessary for appropriate antibiotic choice. 
Although the etiology of febrile neutropenic infections 
has shifted from gram negative to gram positive 
organisms in many centers, our results show that 
infections with gram negative bacteria continue to 
predominate in febrile neutropenic attacks in our center. 
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